Pfizer Inc on Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in broader age groups.
A syringe and vial are seen in front of a displayed Pfizer logo in this illustration taken June 24, 2021. REUTERS/Dado Ruvic/Illustration/File Photoon Tuesday raised the full-year sales forecast for its COVID-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in broader age groups.
The company said it is also on track to deliver 2.3 billion doses of the vaccine, out of the roughly 3 billion it plans to make this year. Driven by an unprecedented vaccination drive against the COVID-19 pandemic globally, Pfizer's shot has quickly become one of the best-selling products in the company's roughly 172-year history. The company equally splits expenses and profit from the vaccine with its German partner BioNTech .
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Long Covid: What to Know About Lingering Symptoms of a Covid-19 InfectionWhat causes long Covid? Are certain people more susceptible to getting it? What’s the deal with long Covid and brain fog? Here’s what the latest research, as well as doctors and patients, say about the condition.
Lire la suite »
COVID-19 live updates: White House press secretary Jen Psaki tests positiveNEW: White House press sec. Jen Psaki reveals that she tested positive for COVID-19 and has been experiencing mild symptoms. Psaki said she chose not to travel with Pres. Biden to the G-20 summit after members of her household tested positive last week.
Lire la suite »
Global Covid-19 deaths surpass five millionThe number of people who have died from Covid-19 around the world surpassed five million early Monday, according to data held by the Johns Hopkins University Coronavirus Resource Center
Lire la suite »